NVAC subcommittees, or working groups, address topical issues in a timely manner. Each subcommittee has a specific charge, a timeline, and identified membership which may include nonmember consultants. The subcommittees are chaired by NVAC members. The Office of Infectious Disease and HIV/AIDS Policy (OIDP) is responsible for staffing the subcommittees and aiding the chairs. Current Subcommittees Innovation in Immunization Subcommittee (2022 - Present) Innovation in Immunization Subcommittee Charge* Vaccine Safety Subcommittee (2022 - Present) Vaccine Safety Subcommittee Charge* Select Former Subcommittees Vaccine Confidence Subcommittee (2019 - 2022) Understanding vaccine confidence and hesitancy is key to ensuring high vaccination rates and saving lives. To build understanding of vaccine confidence, the NVAC was charged with providing a report that synthesizes and summarizes evidence and research addressing vaccine confidence across the lifespan and recommends new and implementable strategies and approaches to sustaining and increasing confidence across the lifespan. Learn more about this subcommittee. Immunization Equity Subcommittee (2019 - 2021) Immunization disparities—including differences in vaccination rates by age, socioeconomic status, race and ethnicity, and geographic areas—persist in the United States. To improve health equity in immunization, NVAC was charged with developing comprehensive recommendations to inform a national strategy for ending immunization disparities in the United States. Learn more about this subcommittee. National Vaccine Plan Subcommittee (2019 - 2019) To remain nimble and responsive to the evolving landscape of the immunization system, the U.S. Department of Health and Human Services will release an updated 3-5 year National Vaccine Plan (NVP) in 2020. This plan will emphasize the importance of vaccination across the lifespan. NVAC was charged with developing recommendations that will inform planning activities for the new NVP. The committee approved the recommendations in Sept. 2019 and released the final report in 2020: 2020 National Vaccine Plan Development: Recommendations from the National Vaccine Advisory Committee. Learn more about this subcommittee. Human Papillomavirus (HPV) Vaccination Working Group (2018 – 2018) As HPV vaccination rates continue to remain low, NVAC was charged in 2018 to provide a brief report by June 2018 with recommendations to strengthen the effectiveness of national, state, and local efforts to improve HPV vaccination coverage rates. The working group completed the report: Strengthening the Effectiveness of National, State, and Local Efforts to Improve HPV Vaccination Coverage in the United States: Recommendations of the National Vaccine Advisory Committee in June 2018 In 2013, NVAC was charged with reviewing the current state of HPV immunization to understand the root cause(s) for low vaccine uptake and identify existing best practices. The working group’s report was released in 2015: Overcoming Barriers to Low HPV Vaccine Uptake in the United States: Recommendations from the National Vaccine Advisory Committee. Mid-course Review Working Group (2014 – 2017) Charged with conducting a Mid-course Review of the 2010 National Vaccine Plan and Implementation Plan, the working group completed the report: Evaluation of the 2010 National Vaccine Plan Mid-course Review: Recommendations from the National Vaccine Advisory Committee in February 2017. Maternal Immunization Working Group (2012 – 2016) NVAC was charged in 2012 with reviewing the state of maternal immunizations and existing best practices, the working group completed the report: Reducing Patient and Provider Barriers to Maternal Immunizations in June 2014 and Overcoming Barriers and Identifying Opportunities for Developing Maternal Immunizations in September 2016. Learn more about this working group. *People using assistive technology may not be able to fully access information in these files. For assistance, contact the HHS Office of Infectious Disease and HIV/AIDS Policy by emailing Ann.Aikin@hhs.gov.